The strong efficacy and safety data support NKX019's potential as a differentiated CAR NK therapy in autoimmune disease. Watch for FDA meeting outcomes and registrational dose selection in H1 2027, which will determine the path to pivotal trials.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $1.59entry
- T+1 · 7d ago −15.09%α −14.73% · $1.35
- T+5 · 18h ago −23.90%α −22.21% · $1.21
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Nkarta announced positive initial clinical data from its Ntrust program for NKX019 in myositis and systemic sclerosis, showing high response rates and a favorable safety profile with no CRS, ICANS, or GvHD. The company plans to discuss registrational pathways with the FDA and expects to report additional data in H1 2027.
Key Facts
- In myositis, 5/6 (83%) patients at 4 billion cells/dose achieved moderate or major TIS responses.
- In systemic sclerosis, 6/7 (86%) patients at 4 billion cells/dose achieved rCRISS-25 response or greater.
- No CRS, ICANS, IEC-HS, or GvHD observed across 40 patients in five indications.
- Median mRSS reduction of 15 points at Day 90 in systemic sclerosis; 71% of patients had ≥50% reduction.
- Nkarta plans FDA interactions to discuss registrational pathways and expects dose selection data in H1 2027.
- Cash and investments were $216.0 million as of Q3 2026, providing runway into 2027.
Financial Impact
Positive clinical data in two autoimmune indications with registrational intent; no financial figures stated beyond cash position of $216M.
Risk Factors
- Data are from small patient numbers with limited follow-up and may change as more data accrue.
- No head-to-head comparisons with approved therapies; cross-trial comparisons are unreliable.
- Registrational pathway and FDA alignment are uncertain; the company is pre-IND for these indications.
- Cash burn continues; $216M may not be sufficient to complete development without additional financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3398226 |
Track record
13 reports on NKTX
5 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +31.21% at T+5 after the Nov 5, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
- Nov 9, 20267d ago Press Release Bullish 7/10 Viewing Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
- Nov 6, 202610d ago 8-K Neutral 3/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Bearish 5/10 Entry $1.73 to $1.59 Now $1.21 +30.06% ▲ +8.09% +10.46% vs SPY
- Aug 10, 202614w ago 8-K Bearish 6/10 Entry $2.33 to $2.39 Now $1.21 +48.07% ▼ −2.58% −2.32% vs SPY
- May 12, 202626w ago Press Release Neutral 4/10 Entry $3.06 to $3.06 Now $1.21 −60.46% · 0.00% +0.00% vs SPY
- Apr 15, 202630w ago Press Release Bullish 7/10 Entry $2.80 to $3.47 Now $1.21 −56.79% ▲ +23.93% +22.71% vs SPY
- Apr 6, 202632w ago EFFECT Bearish 7/10 Entry $2.36 to $2.25 Now $1.21 +48.73% ▲ +4.66% +4.72% vs SPY
- Mar 25, 202633w ago 8-K Bearish 6/10 Entry $2.14 to $2.06 Now $1.21 +43.46% ▲ +3.74% +2.06% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers